STEVENSON, Md., Feb. 08, 2017 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Fenix Parts, Inc. (Nasdaq:FENX) (“Fenix” or the “Company”) securities during the period between May 14, 2015 and October 12, 2016, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until March 13, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Fenix securities during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Fenix had an inadequate methodology for inventory valuation, had an inadequate methodology to calculate goodwill impairment, and was engaging and/or had engaged in conduct that would result in a U.S. Securities and Exchange Commission investigation (“SEC”).
According to the complaint, following an October 13, 2016 announcement revealing that the Company was not able to file a quarterly report and that it received a subpoena from the SEC, the value of Fenix shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Fenix securities purchased on or after May 14, 2015 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 [email protected]


Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 



